Prosecution Insights
Last updated: August 18, 2026

Examiner: COLEMAN, BRENDA LIBBY

Tech Center 1600 • Art Units: 1600 1624 1626 1644

This examiner grants 75% of resolved cases

Performance Statistics

74.6%
Allow Rate
+14.6% vs TC avg
1,666
Total Applications
+15.6%
Interview Lift
881
Avg Prosecution Days
Based on 1633 resolved cases, 2023–2026

Rejection Statute Breakdown

3.5%
§101 Eligibility
15.8%
§102 Novelty
8.5%
§103 Obviousness
52.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18252217 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS Non-Final OA Merck Sharp & Dohme LLC
18423776 TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF Non-Final OA NOVARTIS AG
17768508 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES Non-Final OA Merck Patent GmbH
18570761 METHOD FOR PRODUCING ISOXAZOLINECARBOXYLIC ACID DERIVATIVES Non-Final OA BAYER AKTIENGESELLSCHAFT
18856782 NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Non-Final OA SANOFI
18273678 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF COMPOUNDS THAT PROTECT AGAINST LIPOFUSCIN CYTOTOXICITY Final Rejection Cornell University
18720074 HETEROCYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF Non-Final OA CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month